Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical vs MUD Hematopoietic Cell Transplantation for Children and AYA With Acute Leukemia or MDS
NCT05457556Phase 3Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Mar 2023
- Primary completion
- Jun 2026
- Modality
- Stem Cell Therapies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL) and 1 more (3 arms), sponsored by Children's Oncology Group. Primary endpoints: Severe Graft Versus Host Disease at 1 year and Disease Free Survival at 1 year. Started Mar 2023; status: active, not recruiting.
02
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05457556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457556.